Literature DB >> 10974585

In-vitro synergistic activity of the combination of ampicillin and arbekacin against vancomycin-and high-level gentamicin-resistant Enterococcus faecium with the aph(2")-Id gene.

V Kak1, I You, M J Zervos, R Kariyama, H Kumon, J W Chow.   

Abstract

The combination of ampicillin plus arbekacin produced synergistic killing against 8 of 13 vancomycin-, ampicillin-, gentamicin-, and streptomycin-resistant Enterococcus faecium isolates that possess the high-level gentamicin resistance gene, aph(2")-Id. This combination may prove useful in treating infections caused by multiresistant enterococci.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10974585     DOI： 10.1016/s0732-8893(00)00155-3

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN： 0732-8893            Impact factor:   2.803


  4 in total

1.  Clinical efficacy and safety of arbekacin for high-risk infections in patients with hematological malignancies.

Authors:  Katsuhiro Miura; Masaru Nakagawa; Hiromichi Takahashi; Yoshihito Uchino; Hitomi Kodaira; Noriyoshi Iriyama; Masashi Sakagami; Shimon Ohtake; Sumiko Kobayashi; Atsuko Hojo; Daisuke Kurita; Yujin Kobayashi; Machiko Kusuda; Yukio Hirabayashi; Yoshihiro Hatta; Masami Takei
Journal:  Int J Hematol       Date:  2015-12-29       Impact factor: 2.490

Review 2.  Clinical Usefulness of Arbekacin.

Authors:  Jae Hoon Lee; Chang-Seop Lee
Journal:  Infect Chemother       Date:  2016-03-31

Review 3.  Intrinsic and acquired resistance mechanisms in enterococcus.

Authors:  Brian L Hollenbeck; Louis B Rice
Journal:  Virulence       Date:  2012-08-15       Impact factor: 5.882

4.  Evaluation of combination effects of ethanolic extract of Ziziphus mucronata Willd. subsp. mucronata Willd. and antibiotics against clinically important bacteria.

Authors:  Olufunmiso Olusola Olajuyigbe; Anthony Jide Afolayan
Journal:  ScientificWorldJournal       Date:  2013-04-24
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.